<?xml version="1.0" encoding="UTF-8"?>
<p id="Par112">Many virus-targeting mAbs are also currently in clinical trials. For example, Ebolavirus is a highly lethal pathogen that causes 25–90% mortality in humans. Therapeutic mAbs for ebolavirus infection have been derived from B cells of vaccinated human donors or survivors [
 <xref ref-type="bibr" rid="CR230">230</xref>–
 <xref ref-type="bibr" rid="CR232">232</xref>]. Impressively, human mAb114, which is derived from sorted memory B cells targeted to the Zaire ebolavirus glycoprotein, protects macaques when administered as late as 5 days after challenge [
 <xref ref-type="bibr" rid="CR231">231</xref>]. Clinical trials for this drug are at Phase I (NCT03478891), Phase II and III (NCT03719586).
</p>
